Evidence linking amyloid beta (Aβ) cellular uptake and toxicity has burgeoned, and mechanisms underlying this association are subjects of active research. Two major, interconnected questions are whether Aβ uptake is aggregation-dependent and whether it is sequence-specific. We recently reported that the neuronal uptake of Aβ depends significantly on peptide chirality, suggesting that the process is predominantly receptor-mediated. Over the past decade, the cellular prion protein (PrP<sup>C</sup>) has emerged as an important mediator of Aβ-induced toxicity and of neuronal Aβ internalization. Here, we report that the soluble, nonfibrillizing Aβ (1–30) peptide recapitulates full-length Aβ stereoselective cellular uptake, allowing us to decouple aggregation from cellular, receptor-mediated internalization. Moreover, we found that Aβ (1–30) uptake is also dependent on PrP<sup>C</sup> expression. NMR-based molecular level characterization identified the docking site on PrP<sup>C</sup> that underlies the stereoselective binding of Aβ (1–30). Our findings therefore identify a specific sequence within Aβ that is responsible for the recognition of the peptide by PrP<sup>C</sup>, as well as PrP<sup>C</sup>-dependent cellular uptake. Further uptake stereodifferentiation in PrP<sup>C</sup>-free cells points toward additional receptor-mediated interactions as likely contributors for Aβ cellular internalization. Taken together, our results highlight the potential of targeting cellular surface receptors to inhibit Aβ cellular uptake as an alternative route for future therapeutic development for Alzheimer’s disease.

Alzheimer’s disease | amyloid β | prion protein (PrP) | mirror-image peptides | receptor-mediated internalization

Aβ (amyloid β) is an aggregation-prone peptide, typically ranging in length from 36 to 43 amino acids, released into the extracellular matrix by the proteolytic cleavage of the transmembrane amyloid precursor protein (APP) (1). Formation of amyloid plaques is a hallmark of Alzheimer’s disease (AD); however, it is the soluble Aβ aggregation intermediates, often referred to as oligomers, that are the most neurotoxic species (2, 3). While Aβ degradation is facilitated by cellular uptake via glial cells (4), increasing evidence suggests that intracellular accumulation of Aβ may play an early role in AD pathogenesis (5–7), including mitochondrial dysfunction (8), synaptic impairment (7), and increased seeding and prion-like cellular propagation (9). Cellular uptake of soluble, nanomolar concentrations of Aβ leads to intracellular endosomal and lysosomal Aβ concentration, facilitating the formation of high-molecular-weight species capable of seeding amyloid fibril growth (10). This cell-uptake-induced aggregation has been shown to contribute to cellular death, ultimately leading to the release of amyloid species to the extracellular matrix (11). Thus, elucidating the mechanisms by which Aβ is internalized and accumulated inside the cells becomes critical to better understanding the early development of AD.

Various Aβ cellular internalization mechanisms have been reported, such as pore formation (3, 12), endocytosis (13), and receptor-mediated uptake (14). Over the past decade, numerous cell-surface receptors of Aβ have been proposed for the uptake of Aβ. These include the α7 nicotinic acetylcholine receptor (15) and the low-density lipoprotein receptor-related protein-1 (LRP1) (16, 17). Inhibition of soluble Aβ species interacting with the cell surface (18), membrane receptors (19), or blocking Aβ uptake (16) have been shown to reduce Aβ-induced toxicity. Over 400 clinical trials targeting Aβ aggregation have failed (20). In late 2019, the Aducanumab antibody that binds soluble Aβ aggregates showed some limited benefit in a phase III clinical trial (21), supporting the hypothesis that Aβ aggregation is important in AD. Targeting soluble, toxic forms of oligomeric Aβ remains the most promising avenue for AD therapeutic development, but it needs to be substantially improved to make real impact on lives of AD patients. Targeting interactions of Aβ with high-affinity receptors that lead to Aβ cellular internalization may offer a promising alternative for therapeutic development.

Using a cell-based screen of 225,000 clones from a mouse brain complementary DNA library, Strittmatter and coworkers found the cellular prion protein (PrP<sup>C</sup>) binds to Aβ oligomers with the highest affinity as compared to the clones screened, displaying a dissociation constant less than 100 nM (22), leading to a PrP<sup>C</sup>-dependent inhibition of long-term potentiation (LTP) in neurons (22) and memory impairment in AD mouse models (23). Subsequent work demonstrated that the PrP<sup>C</sup>-Aβ interaction occurs in AD patients (24) and drives an aberrant signaling cascade mediated by mGluR5 (25, 26) leading to Fyn kinase phosphorylation in neurons. Additional research has demonstrated that PrP<sup>C</sup>−

Significance

Amyloid β (Aβ) aggregation has been the therapeutic target of several Alzheimer’s disease (AD) clinical trials. Aβ exists in many different aggregated forms, making it exceedingly challenging to target. Evidence links intracellular Aβ accumulation and AD pathogenesis. We report that amino acids 1 to 30 of Aβ, Aβ (1–30), do not aggregate yet display cellular uptake stereospecificity when compared to its mirror image, suggesting that Aβ uptake is predominantly receptor-mediated and may be independent from its aggregation state. Additionally, we found Aβ (1–30) internalization to depend on PrP<sup>C</sup> expression. Aβ (1–30) thus represents a powerful tool to study mechanisms of Aβ cellular internalization and suggests that Aβ uptake could be modulated by therapeutically targeting high-affinity Aβ receptors.


The authors declare no competing interest. This article is a PNAS Direct Submission. Published under the PNAS license.

1A.R.F. and G.P.R. contributed equally to this work.
2To whom correspondence may be addressed. Email: glennm@ucsc.edu or jraskato@ucsc.edu.

This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2009238117/-/DCSupplemental.

First published November 2, 2020.
conjunction with LRPI, facilitates cellular uptake of Aβ (16), causing an increase in Fyn kinase phosphorylation.

In previous experiments we compared toxicity of l- and d-Aβ42. We found that, under conditions where l-Aβ42 reduced cell viability over 50%, d-Aβ42 was either nontoxic (PC12) or under 20% toxic (SH-SY5Y) (27). We later showed that l-Aβ is taken up approximately fivefold more efficiently than d-Aβ (28), suggesting that neuronal Aβ uptake and toxicity are linked. Here, we used the mirror-image strategy to pinpoint specific sites within Aβ that are responsible for this stereodifferentiation. Furthermore, we used PrPε-transfected cells as a high-affinity receptor of Aβ to showcase the relevance of receptor-mediated mechanisms leading to cellular internalization.

**Results**

We first examined how PrPε expression influenced Aβ uptake in HEK293T cells, which do not naturally express PrPε (29). We chose the Aβ40 system for its lower propensity to form pores in cellular membranes (30) and lipid bilayers (12), therefore making it suitable to study receptor-mediated interactions. We synthesized Aβ peptides by solid-phase peptide chemistry, yielding purities exceeding 96% (SI Appendix, Figs. S1–S5). For uptake studies, we N-terminally labeled Aβ (1–40) peptides with 5(6)carboxytetramethylrhodamine (TAMRA), which we have shown previously does not change Aβ aggregation and toxicity (28). As quantitated by flow cytometry (Fig. 1 B and C), there is a 3.8-fold difference between l- and d-Aβ. When PrPε is transfected and expressed, both l-Aβ40 and d-Aβ40 values increase (fourfold and 2.2-fold, respectively), and the difference between l-Aβ40 and d-Aβ40 rises to 7.3-fold. Transfection buffer had no effect on cellular association (SI Appendix, Fig. S7A) and increased PrPε expression levels result in a dose-dependent behavior (SI Appendix, Fig. S7B). Z stacks obtained from confocal imaging reveal that Aβ40 peptides are mostly internalized rather than bound to the cellular membrane (Fig. 1 D–G), qualitatively showing an increase in cellular uptake for l-Aβ40 compared to d-Aβ40 (green color indicated with arrows) (Fig. 1 D and F). Furthermore, PrPε-expressing HEK293T cells display an increase in internalized TAMRA-l-Aβ40 (Fig. 1 E and G) relative to untransfected cells, which is consistent with the flow cytometry results. While l-Aβ40 uptake increases fourfold upon PrPε expression, d-Aβ40 uptake also increases (2.2-fold), suggesting that both stereospecific and nonspecific interactions between PrPε–Aβ40 might be involved in increased Aβ uptake, with stereospecific interactions contributing at a higher degree. Additionally, Aβ40 uptake is reduced for PrPε constructs that delete (∆CR and ∆100–109 PrPε) or mutate (G5 PrPε) the putative binding site of Aβ on wild-type (WT) PrPε (SI Appendix, Fig. S8) (22). Intriguingly, OCR PrPε, which mutates four conserved lysines between residues 100 and 109 known to influence a PrPε–Aβ interaction (31) to glutamines, does not result in a decrease in uptake.

Enantiomeric peptides are usually employed to differentiate receptor-mediated from achiral-based toxicity and uptake mechanisms, such as pore formation or passive permeability (32). However, recent work performed by Craik and coworkers demonstrated that the chirality of membrane phospholipids can also modulate interactions of peptides with membranes (33). To address this effect, we performed lipidosome association controls in lipid unilamellar vesicles composed of 99% phosphatidylcholine (PC) (achiral headgroups) and 1% brain-derived phosphatidylserine (PS) (chiral headgroups). Our results show that both TAMRA-l-Aβ40 and TAMRA-d-Aβ40 associate to liposomes at similar levels, establishing that the observed stereoelectivity of cellular uptake of Aβ is not due to chiral interactions with the lipid bilayer itself (SI Appendix, Fig. S9).

We then sought to investigate sequences within Aβ responsible for these stereospecific interactions. Thus, we synthesized truncated variants of Aβ including the flexible N-terminal region
(Fig. 2A), which we hypothesized to be more available for intermolecular interactions given its greater flexibility when compared to the hydrophobic C terminus of Aβ (34). We observed in SH-SY5Y cells that Aβ (1–16) sequence retained little stereoselectivity (1.4-fold of L over D). In contrast, substantial stereodifferentiation arose with amino acids 16 to 30, where Aβ (16–30) and Aβ (1–30) sequence showed a 4.2-fold and 4.3-fold L vs. D difference, respectively (Fig. 2B). These differences are comparable to full-length Aβ40. We then tested these sequences in PrP<sup>C</sup>-transfected HEK293T cells (Fig. 2C). While stereodifferentiation for the different Aβ fragments in untransfected cells followed the same trend as in SH-SY5Y cells, surprisingly we did not observe a PrP<sup>C</sup>-dependent uptake for Aβ (1–16). However, L-Aβ (1–30) showed a PrP<sup>C</sup>-dependent increase in uptake, with trends similar to full-length L-Aβ40. Importantly, the Aβ (1–30) segment is soluble, does not aggregate, and retains a random-coil conformation for at least 24 h (SI Appendix, Figs. S10 and S11), which is consistent with previous studies on the Aβ (1–28) system (35). These properties of Aβ (1–30) pointed to the existence of a specific site, responsible at least in part, for Aβ interactions with PrP<sup>C</sup>, as well as its cellular internalization.

Since the nonaggregating Aβ (1–30) was sufficient to recapitulate the trends in PrP<sup>C</sup>-dependent uptake stereoselectivity, we studied its interaction with PrP<sup>C</sup> using NMR. We collected <sup>1</sup>H-<sup>15</sup>N heteronuclear single quantum coherence (HSQC) spectra on uniformly <sup>15</sup>N-labeled PrP<sup>C</sup> with or without L- or D-Aβ (1–30). Intensity ratios (I/I<sub>0</sub>) and weighted averaged chemical shifts (Δ) were calculated for each assigned amino acid (data in SI Appendix, Tables S1 and S2) and then plotted as bar graphs (Fig. 3).

Discussion

Previous studies have shown that PrP<sup>C</sup> preferentially interacts with oligomeric Aβ over nonaggregated Aβ (22, 38). In contrast, we have shown that nonaggregating Aβ (1–30) can interact with PrP<sup>C</sup> and lead to increased cellular uptake. Importantly, soluble L-Aβ (1–30) interacts with PrP<sup>C</sup> between residues 94 and 110, which is the known docking site of oligomeric Aβ (22, 37), thus demonstrating that the absence of Aβ residues 31 to 40 does not affect the locus of binding to PrP<sup>C</sup>. We also observed higher PrP<sup>C</sup>-dependent uptake of the natural L-isomers of both Aβ (1–30) and Aβ40 when compared to the D-enantiomers, suggesting a docking site on PrP<sup>C</sup> facilitating this interaction.

It has been proposed that an Aβ binding partner relevant to synaptic dysfunction in AD will be 1) oligomer-specific, 2) high-affinity, and 3) present in adult synapses (39). Previous studies have demonstrated that PrP<sup>C</sup> contains these three characteristics (16, 22, 25, 26, 38–40). However, our results demonstrate that PrP<sup>C</sup> can bind to Aβ (1–30), which is highly soluble, does not aggregate, and remains stable as a single species with a random-coil conformation. This conceivably points to Aβ (1–30)’s not being a higher-order oligomer while still retaining stereoselective uptake and PrP<sup>C</sup> binding. This implies that Aβ (1–30) may be the amino acid sequence within full-length Aβ that allows for a PrP<sup>C</sup>–Aβ interaction, whereas residues 31 to 40 in full-length Aβ could have a larger and main role in promoting Aβ oligomerization. Furthermore, oligomerization could potentially enrich for the preferred conformation of Aβ (1–30) that facilitates an interaction with PrP<sup>C</sup>, which is in agreement with our results showing higher PrP<sup>C</sup>-dependent cellular uptake levels of Aβ40 when compared to Aβ (1–30) (Fig. 2). This is supported by recent evidence showing that different oligomeric Aβ conformations, measured by accessibility of conformational antibodies, bind with different affinities to PrP<sup>C</sup> (41).

Fig. 2. Cellular uptake of the Aβ peptides studied in this work. (A) Sequence of Aβ peptides tested. (B) Mean FACS results in SH-SY5Y cells normalized against L-Aβ40 (5 μM peptide, 15-h incubation). Bars show mean fluorescence with error bars for SD of three biological replicates. (C) Mean FACS results in HEK293T cells with and without PrP<sup>C</sup> expression, normalized against L-Aβ40 (5 μM peptide, 2-h incubation). Bars show mean fluorescence with error bars for SD of two biological replicates.
Mounting evidence shows physiological relevance to a PrP<sup>C</sup>–Aβ interaction. For example, monoclonal antibodies directed to target PrPC–Aβ binding sites protected against the Aβ-mediated block of LTP in C57BL/6J mice in vitro and in vivo (42). However, other studies have exhibited PrP<sup>C</sup>-independent neurotoxicity in AD models (43, 44). From our results, we observed a PrP<sup>C</sup>-independent, but still stereoselective, uptake of L-Aβ (16–30). While PrP<sup>C</sup>–Aβ binding seems to require amino acids (1–30), the (16–30) sequence may be sufficient for other chiral interactions with cells, and resolving these chiral interactions may reveal novel receptors as targets to develop therapeutics to inhibit Aβ cellular uptake beyond PrP<sup>C</sup>. For example, Aβ oligomers have been shown to bind to the neuronal cell surface receptor LilrB2, producing deleterious effects on hippocampal LTP in mice, resulting from impaired neuronal signaling and thus generating synaptotoxicity (45). Further studies of Aβ–LilrB2 interactions led to the identification of Aβ moiety 16–21 (1<sup>6</sup>KLVFFA21) as responsible for the interaction with LilrBr2, and small molecules designed to block this interaction were shown to reduce Aβ toxicity in vitro models (19). Additionally, the tyrosine kinase EphB2 receptor, which modulates the activity of N-methyl-D-aspartate–type glutamate receptors, has been reported to interact with Aβ oligomers (46), and blocking this interaction with small peptides results in the rescue of impaired synaptic plasticity and memory deficits in AD APPsw/PS1dE9 (APP/PS1) transgenic mice (47). Other receptors linked in AD pathogenesis include α7 nicotinic acetylcholine receptor (15) or LRP1 (16, 17).

While receptor-mediated interactions of Aβ can lead to downstream neurotoxicity, there are additional mechanisms by which Aβ–membrane interactions may be deleterious. Lipid membranes themselves are known to bind Aβ by either the phospholipid head groups (48) or through the interaction of additional membrane components such as cholesterol, the later reported to catalyze Aβ aggregation in synthetic lipid membranes (49). Cellular plasma membranes also promote Aβ self-assembly, aggregation, and internalization, in a process that generates cytotoxic Aβ species (50). In contrast, Aβ (1–30) does not aggregate, yet we showed it can participate in cell-surface interactions that lead to stereoselective cellular uptake. An increase in intracellular Aβ can create local gradients of particularly high concentrations of Aβ which may favor intracellular Aβ aggregation, ultimately leading to increased pathogenicity and extracellular release of Aβ aggregates which can further act as a seed for fibril growth (10, 11). Abnormally high concentrations of intracellular Aβ resulting from Aβ uptake can also result in decreased Aβ solubility, promoting a homoeostatic intracellular imbalance that could trigger amyloid formation (51). Factors controlling Aβ trafficking into cells are therefore of seminal importance to prevent AD pathogenesis (52), and modulating receptor-mediated Aβ uptake could represent a promising strategy for AD disease prevention. In addition, sporadic AD and resulting dementia may be associated with infections of brain tissue with pathogens that are known to enter into neurons, such as herpes simplex virus 1 (HSV-1) and porphyromonas gingivalis (53, 54). As a result, those HSV-1–infected cells produce more Aβ (55), a mechanism that has recently been exploited for the development of brain-tissue models of AD (56).

Taken together, we found that the soluble, nonfibrillizing Aβ (1–30) peptide recapitulates uptake stereoselectivity of full-length Aβ (28). Our findings show that molecular cell-surface recognition of Aβ underlying its internalization is largely due to the amino acid sequence and not the state of aggregation. We found that the soluble Aβ (1–30) peptide segment is both necessary and sufficient to recapitulate stereospecific and PrP<sup>C</sup>-dependent uptake. Solution NMR demonstrated that L-Aβ (1–30) interacts with WT-PrP between residues 94 and 110, in agreement with previous studies (22, 37), thus validating L-Aβ (1–30) as model system to study this disease-relevant interaction. Deletion of this PrP<sup>C</sup> site resulted in a decrease in PrP<sup>C</sup>-dependent uptake of Aβ40, further demonstrating a functional interaction between PrP<sup>C</sup> and the (1–30) segment of Aβ. These results are consistent with a model in which the relatively flexible segment (1–30) is responsible for cell-surface recognition, whereas the hydrophobic C terminus orchestrates Aβ aggregation and may act in membrane docking and/or perforation activity (12, 30). Future efforts targeting this specific sequence, as well as its cellular binding partners, may hold therapeutic potential to inhibit Aβ toxicity.

**Materials and Methods**

**Synthesis of Aβ Peptides.** Aβ and derived peptides were synthesized by solid-phase chemistry, following our previously reported protocols (27). L-Aβ<sub>40</sub> and o-Aβ<sub>40</sub> were synthesized using Tentagel PHB resin (Rapp Polymere) to achieve carboxyl C terminus, while Aβ fragments were synthesized using Rink Amide resin (Cresola) to yield amidated C terminus. All syntheses were performed on a CEM Liberty Blue automated microwave-assisted peptide synthesizer at 0.1 mM scale relative to resin loading. Thirty percent
Cell lysates were treated with recombinant PNGase F (New England Biolabs) 150 mM sodium chloride (NaCl), 1 mM ethylenediaminetetraacetic acid (EDTA) and 1-hydroxy-7-azabenzotriazole (HOAt, 16 mg, 20 eq.), and diisopropylethylamine (10 eq.), was dissolved in 5 mL of DMF and added to the resin. The TAMRA-resin mixture was agitated on a rotational shaker for 24 h protected from light. The resin was then washed with DMF (three times) and DCM (two times) and vacuum-dried for 30 min. Reaction completion was confirmed by a cleavage and mass spectrometry analysis of a small fraction of reacted resin. Purification of the peptides was performed as described above, yielding peptides with purity exceeding 96% (SI Appendix, Figs. S3–S5). TAMRA
\textsubscript{max} was 550/580 nm.

**Flow Cytometry Experiments.** Flow cytometry experiments were performed as previously described (28). Briefly, lyophilized TAMRA-labeled peptides were dissolved in 20 mM NaOH and diluted to a final concentration of 5 µM using SH-SYSY cell media. Original seeding media was removed from cells and replaced with the freshly prepared 5 µM TAMRA-labeled peptide solution. For control cells, original seeding media was replaced by fresh cell media with no peptide. Cells were incubated for the desired amount of time at 37 °C. Following incubation time, cells were washed twice with 1× PBS, pH 7.4, trypsinized for 5 min, resuspended in cell culture media, centrifuged at 120 × g for 10 min, resuspended in 1× PBS, pH 7.4, centrifuged at 120 × g for 10 min, and then incubated for 20 min with 1× PBS, pH 7.4, containing 0.1% live/dead fixable violet dye (Thermo Fisher Scientific). Cells were then centrifuged and resuspended in FACS buffer solution (5 mM EDTA and 0.5% BSA in 1× Dulbecco’s PBS [DPBS]). A population of 1 × 10^6 cells was analyzed on a BD FACS Aria II flow cytometer. Live/dead cell dye was excited at 405 nm and fluorescence was detected through a 450/30 nm filter. TAMRA was excited at 571 nm and fluorescence was detected through a 580/10-nm filter. Collected data were processed and analyzed using FlowJo software.

**Confocal Microscopy Experiments.** HEK293T cells were plated in an eight-well chamber slide (Ibidi) as described in Cellular Cultures. Cells were dosed with TAMRA-Aj peptides at 5 µM concentration, following the same sample re-constitution procedures as detailed for FACS. Cells were incubated for 2 h at 37 °C. After incubation, cells were washed twice with 1× DPBS (HyClone) and incubated for 20 min with a solution containing 5 µg/mL Hoechst 33342 dye (nuclear stain, \textsubscript{max} 350/461 nm; Thermofisher), 5 µg/mL wheat germ agglutinin Alexa Fluor dye (membrane stain, \textsubscript{max} 650/668 nm; Thermofisher), and 5 µg/mL PrP(8B4) Alexa Fluor dye (PrP-specific stain, \textsubscript{max} 490/525 nm; Santa Cruz Biotechnology) in DPBS. After incubation, dye-containing solution was removed and cells were washed twice with 1× DPBS and resuspended again in 1× DPBS. Confocal images were acquired on a Leica SPS confocal microscope using a 63×/1.4 to 0.6 oil immersion objective. Z stacks were collected by three sequential scans (PrP-Alexa Fluor & wheat germ agglutinin Alexa Fluor/405 channel) to avoid spectral overlapping. Images were analyzed using Imaris software.

**NMR Experiments.** Lyophilized uniformly ^15N-labeled PrP\textsuperscript{C} constructs were first suspended in water until fully solubilized and concentrations were checked using the absorbance at 280 nm (A\textsubscript{280}) with the proper extinction coefficient. 1- or 6- Aj (1-30) was first dissolved in 4 mM in 20 mM potassium hydroxide (KOH) and sonicated for 30 s in a bath sonicator until fully solubilized. The Aj (1-30) solution was then subsequently diluted to 400 µM with 10 mM 2-(N-morpholino)ethanesulfonic acid (MES) at pH 6. NMR samples were contained 100 µM WT PrP with or without 200 µM WT or 6-Aj (1-30) in 10 mM MES buffer with 10% D\textsubscript{2}O and the pH was adjusted to 6.6 using 600 mM KOH. Samples were loaded into a Shigemi NMR tube (BMS-005B; Wilmad Glass) and a 1H-15N HSQC spectrum was collected at 25 °C on an 800-MHz spectrometer (Bruker) at the University of California, Santa Cruz NMR Facility. NMR spectra were analyzed with NMRPipe (60) and Sparky. Protein assignments were achieved using previously determined values (58). Intensity ratios (I/bar) were calculated by dividing the peak intensity with Aj (1-30) (I) by the peak intensity of WT PrP\textsuperscript{C} alone (bar). The weighted average chemical shifts (\bar{\delta}) were calculated by the equation \bar{\delta} = \sum_n \delta_n (0.17 \delta_n^2) \text{bar} – (0.17 \delta_n^2) \text{Aj}, where \delta_n\text{bar} and \delta_n\text{Aj} are the Aj (1-30)-induced differences amide proton and nitrogen chemical shifts, respectively.

**Synthetic Liposomes Experiments.** A solution of 10 mg/mL 99:1 l-α-phosphatidylcholine (PC):l-α-phosphatidylserine (PS)-brain (Avanti Polar Lipids) in
DCM was blown down with N₂ to create a lipid film, which was then covered with a wipe and vacuum-desiccated for 3 h. The film was then rehydrated with PBS, pH 7.4, and the liposome solution was rotated for 30 min. After mixing, unilamellar vesicles were extruded on a mini-extruder with a 0.2-μm polycarbonate membrane over a heating block. The lipidic crude solution was passed through the membrane a minimum of 40 times. Dynamic light scattering characterization. Extruded liposomes diameter was measured on a Malvern Zetasizer Nano 2390 particle analyzer using 1-cm path length cuvettes, with five runs of 10 s of run duration per run. Three measurements were taken per run with 0-s delay between measurements.

**Incubation of liposomes with L-A**


**Circular Dichroism Spectroscopy Experiments.** Aβ (1-30) peptides were dissolved to 200 μM concentration (same as for NMR experiments) in 20 mM phosphate buffer, pH 7.4, as previously described. The solution was injected to a Yarac SEC-2000 column at 0.6 mL/min flow rate on a 1260 Agilent Infinity II LC system, using 20 mM phosphate buffer, pH 7.4, as running buffer. Absorbance at 214 nm was used as method of detection. Peptides were incubated at 37 °C for time = 24 h measurements.

**Size-Exclusion Chromatography Experiments.** Aβ (1-30) lyophilized peptides were reconstituted to 200 μM in 20 mM phosphate buffer, pH 7.4. To obtain the circular dichroism (CD) spectra, 400 μL of peptide-containing solution were placed in a quartz 1-mm cell. Spectra were then recorded using a Jasco 1500 CD spectrophotometer, set to a scan range of 180 to 280 nm, a digital integration time of 4 s, and a scan speed of 50 nm/min. Samples were incubated at 37 °C in between measurements.

**Data Availability.** All study data are included in the paper and SI Appendix.


44. I. J. Whitehouse et al., Ablation of prion protein in wild type human amyloid precursor protein (APP) transgenic mice does not alter the proteolysis of APP, levels of amyloid-β or pathologic phenotype. PLoS One 11, e0159119 (2016).


